It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...

with other rivals including Johnson & Johnson’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) and Takeda Pharma’s α4β7 inhibitor Entyvio (vedolizumab), both of which are approved for both ...

The study, published in The Journal of ImmunoTherapy of Cancer, details how an immunoprotected device near the tumor microenvironment containing cells engineered to locally release interleukin-12 ...

Blocking IL-23 may block other proinflammatory cytokines ... of skin disease and the onset of joint disease is between 3 and 12 years. “For the majority of our patients with psoriasis, we ...